Advertisement

Journal of Clinical Immunology

, Volume 35, Issue 4, pp 408–415 | Cite as

Neonatal Levels of T-cell Receptor Excision Circles (TREC) in Patients with 22q11.2 Deletion Syndrome and Later Disease Features

  • Kiran A. Gul
  • Torstein Øverland
  • Liv Osnes
  • Lars O. Baumbusch
  • Rolf D. Pettersen
  • Kari Lima
  • Tore G. Abrahamsen
Original Research

Abstract

Purpose

Newborns with severe T-cell lymphopenia, including those with 22q11.2 deletion syndrome (DS), have low numbers of T-cell receptor excision circles (TRECs). The aim of this study was to determine a possible correlation between neonatal TRECs in 22q11.2DS and the development of different phenotypes to elucidate the prognostic value of TREC in this disease.

Methods

In this national survey including 46 patients with 22q11.2DS born after 2005, TREC levels were determined using stored newborn screening blood spots on filter cards. Patients were grouped into quartiles according to their TREC values, except the two infants with thymus aplasia.

Results

The two patients with thymic aplasia had no detectable TREC. The rest had no severe clinical immunodeficiency. There was a significant correlation between low TRECs and the proportion of patients with CD3+CD4+T-cells below the 5th percentile of healthy infants (p = 0.027) as well as the proportion with an abnormal thymus feature either no thymus or remnant thymus as observed during heart surgery (p = 0.022). Significantly lower TRECs (p = 0.019) were found in patients with cardiac defects compared to no such defects. Patients within the lowest quartile of TREC values (<71 TRECs/μL, n = 11) had more frequent severe cardiac defects than the other quartiles (p = 0.010). Eight of these patients in the lowest quartile needed an operation/intervention within two weeks after birth or died because of a cardiac defect.

Conclusion

The low TREC values not only correlate with decreased T-cell immunity, but also with the occurrence of heart defects in the patients.

Keywords

T-cell receptor excision circles 22q11.2 deletion syndrome cardiac defect thymus newborn screening 

Abbreviations

CDC

Centre of disease control

CGH array

Comparative genomic hybridization array

CMV

Cytomegalovirus

COMT

Catechol-O-methyltransferase

DBS

Dried blood spot

DS

Deletion syndrome

FISH

fluorescent in situ hybridization

SCID

Severe combined immunodeficiency

S1

DNA Purification solution

S2

Elution solution

TBX1

T-Box 1

TCR

T-cell receptor

TREC

T-cell receptor excision circles

MAPCA

major aortopulmonary collateral arteries

VSD

Ventricle septum defect

Notes

Acknowledgments

We appreciate the support of Jacalyn Gerstel-Thompson, University of Massachusetts Medical School. We are grateful to Leiv Sandvik, Gaute Nesse for his help with the plasmid preparation, and Grethe Dyrhaug and Monica Åsegg-Atneosen for technical guidance. We also thank Marianne Wright for her help throughout the research and the genetic institutions in Norway, in particular Teresia Wangensteen, for the help with inclusion and genetic characterization of the patients.

Conflicts of Interest

All the authors confirm that no conflict of interest exists.

Supplementary material

10875_2015_153_Fig2_ESM.gif (59 kb)

There is a significant correlation between TREC quartiles and CD3 + CD4+ T-cells (p = 0.027). (GIF 58 kb)

10875_2015_153_MOESM1_ESM.docx (20 kb)
High resolution image (DOCX 20 kb)
10875_2015_153_MOESM2_ESM.tif (80 kb)
ESM 1 (TIFF 80 kb)

References

  1. 1.
    Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics. 2003;112:101–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Devriendt K, Fryns JP, Mortier G, van Thienen MN, Keymolen K. The annual incidence of DiGeorge/velocardiofacial syndrome. J Med Genet. 1998;35:789–90.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Driscoll DA, Salvin J, Sellinger B, Budarf ML, McDonald-McGinn DM, Zackai EH, et al. Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: implications for genetic counselling and prenatal diagnosis. J Med Genet. 1993;30:813–7.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Oskarsdottir S, Vujic M, Fasth A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child. 2004;89:148–51.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet. 1997;34:798–804.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Kitsiou-Tzeli S, Kolialexi A, Fryssira H, Galla-Voumvouraki A, Salavoura K, Kanariou M, et al. Detection of 22q11.2 deletion among 139 patients with Di George/Velocardiofacial syndrome features. In Vivo. 2004;18:603–8.PubMedGoogle Scholar
  7. 7.
    Baldini A. DiGeorge syndrome: an update. Curr Opin Cardiol. 2004;19:201–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, et al. The DNA sequence of human chromosome 22. Nature. 1999;402:489–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Frohn-Mulder IM, Wesby SE, Bouwhuis C, Van Hemel JO, Gerritsma E, Niermeyer MF, et al. Chromosome 22q11 deletions in patients with selected outflow tract malformations. Genet Couns. 1999;10:35–41.PubMedGoogle Scholar
  10. 10.
    Maeda J, Yamagishi H, McAnally J, Yamagishi C, Srivastava D. Tbx1 is regulated by forkhead proteins in the secondary heart field. Dev Dyn. 2006;235:701–10.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Xu H, Cerrato F, Baldini A. Timed mutation and cell-fate mapping reveal reiterated roles of Tbx1 during embryogenesis, and a crucial function during segmentation of the pharyngeal system via regulation of endoderm expansion. Development. 2005;132:4387–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhang Z, Cerrato F, Xu H, Vitelli F, Morishima M, Vincentz J, et al. Tbx1 expression in pharyngeal epithelia is necessary for pharyngeal arch artery development. Development. 2005;132:5307–15.CrossRefPubMedGoogle Scholar
  13. 13.
    Guris DL, Fantes J, Tara D, Druker BJ, Imamoto A. Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet. 2001;27:293–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Verhagen JM, Diderich KE, Oudesluijs G, Mancini GM, Eggink AJ, Verkleij-Hagoort AC, et al. Phenotypic variability of atypical 22q11.2 deletions not including TBX1. Am J Med Genet A. 2012;158A:2412–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Sullivan KE. Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial Syndrome. Immunol Allergy Clin North Am. 2008;28:353–66.CrossRefPubMedGoogle Scholar
  16. 16.
    Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J Mol Med (Berl). 2001;79:631–40.CrossRefGoogle Scholar
  18. 18.
    Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol. 2009;124:522–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Puck JM. Neonatal screening for severe combined immunodeficiency. Curr Opin Pediatr. 2011;23:667–73.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Lingman FJ, Borte S. D.U. von, L. Hammarstrom, S. Oskarsdottir, Retrospective Analysis of TREC Based Newborn Screening Results and Clinical Phenotypes in Infants with the 22q11 Deletion Syndrome. J Clin Immunol. 2014;34:514–9.Google Scholar
  21. 21.
    Cruickshank MN, Pitt J, Craig JM. Going back to the future with Guthrie-powered epigenome-wide association studies. Genome Med. 2012;4:83.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Gerstel-Thompson JL, Wilkey JF, Baptiste JC, Navas JS, Pai SY, Pass KA, et al. High-throughput multiplexed T-cell-receptor excision circle quantitative PCR assay with internal controls for detection of severe combined immunodeficiency in population-based newborn screening. Clin Chem. 2010;56:1466–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr. 1997;130:388–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Lima K, Abrahamsen TG, Foelling I, Natvig S, Ryder LP, Olaussen RW. Low thymic output in the 22q11.2 deletion syndrome measured by CCR9 + CD45RA+ T cell counts and T cell receptor rearrangement excision circles. Clin Exp Immunol. 2010;161:98–107.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Piliero LM, Sanford AN, McDonald-McGinn DM, Zackai EH, Sullivan KE. T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood. 2004;103:1020–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Pierdominici M, Mazzetta F, Caprini E, Marziali M, Digilio MC, Marino B, et al. Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Exp Immunol. 2003;132:323–31.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Shah SS, Lai SY, Ruchelli E, Kazahaya K, Mahboubi S. Retropharyngeal aberrant thymus. Pediatrics. 2001;108:E94.CrossRefPubMedGoogle Scholar
  28. 28.
    Jyonouchi S, McDonald-McGinn DM, Bale S, Zackai EH, Sullivan KE. CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features. Pediatrics. 2009;123:e871–7.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Barrett DJ, Ammann AJ, Wara DW, Cowan MJ, Fisher TJ, Stiehm ER. Clinical and immunologic spectrum of the DiGeorge syndrome. J Clin Lab Immunol. 1981;6:1–6.PubMedGoogle Scholar
  30. 30.
    Bastian J, Law S, Vogler L, Lawton A, Herrod H, Anderson S, et al. Prediction of persistent immunodeficiency in the DiGeorge anomaly. J Pediatr. 1989;115:391–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Jawad AF, McDonald-McGinn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr. 2001;139:715–23.CrossRefPubMedGoogle Scholar
  32. 32.
    Kornfeld SJ, Zeffren B, Christodoulou CS, Day NK, Cawkwell G, Good RA. DiGeorge anomaly: a comparative study of the clinical and immunologic characteristics of patients positive and negative by fluorescence in situ hybridization. J Allergy Clin Immunol. 2000;105:983–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Eberle P, Berger C, Junge S, Dougoud S, Buchel EV, Riegel M, et al. Persistent low thymic activity and non-cardiac mortality in children with chromosome 22q11.2 microdeletion and partial DiGeorge syndrome. Clin Exp Immunol. 2009;155:189–98.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Repetto GM, Guzman ML, Delgado I, Loyola H, Palomares M, Lay-Son G, et al. Case fatality rate and associated factors in patients with 22q11 microdeletion syndrome: a retrospective cohort study. BMJ Open. 2014;4:e005041.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Gittenberger-de Groot AC, Bartelings MM, Deruiter MC, Poelmann RE. Basics of cardiac development for the understanding of congenital heart malformations. Pediatr Res. 2005;57:169–76.CrossRefPubMedGoogle Scholar
  36. 36.
    McCarthy M. Developemental pathways that shape the heart. Lancet. 2014;351:1564.CrossRefGoogle Scholar
  37. 37.
    Eriksen HB, Biering-Sorensen S, Lund N, Correia C, Rodrigues A, Andersen A, et al. Factors associated with thymic size at birth among low and normal birth-weight infants. J Pediatr. 2014;165:713–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Kiran A. Gul
    • 1
    • 2
  • Torstein Øverland
    • 3
  • Liv Osnes
    • 4
  • Lars O. Baumbusch
    • 1
  • Rolf D. Pettersen
    • 2
  • Kari Lima
    • 3
    • 5
  • Tore G. Abrahamsen
    • 3
    • 6
  1. 1.Department of Pediatric Research, Women and Children’s DivisionOslo University Hospital RikshospitaletOsloNorway
  2. 2.Norwegian National Unit for Newborn Screening, Women and Children’s DivisionOslo University Hospital RikshospitaletOsloNorway
  3. 3.Department of Pediatric Medicine, Women and Children’s DivisionOslo University Hospital RikshospitaletOsloNorway
  4. 4.Department of ImmunologyOslo University Hospital RikshospitaletOsloNorway
  5. 5.Department of Endocrinology, Division of MedicineAkershus University HospitalLørenskogNorway
  6. 6.Faculty of MedicineUniversity of OsloOsloNorway

Personalised recommendations